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the protein in the absence of the [2Fe-2S]2+ cluster. A
unique and unexpected feature of biotin synthase is the
incorporation of an arginine guanidino group, as well
as three cysteine thiolates, as ligands to this cluster [8].
In the absence of metal coordination, the arginine
would likely become protonated and be repelled from
the hydrophobic interior of the protein, providing a
plausible role for this conserved residue in sensing the
presence of the cluster. Unfolding of the protein may
be an evolved feature that facilitates repair of the other-
wise deeply buried [2Fe-2S]2+ cluster. In the absence of
efficient cluster repair, BioB degradation may facilitate
more rapid downregulation of biotin production after
only a few turnovers, a feature that could conserve
metabolic energy and promote stationary-phase sur-
vival under nutrient-deprived conditions.
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Figure 1. Ribbon Depiction of the Biotin Synthase Monomer Philadelphia, Pennsylvania 19104
The protein backbone forms an (αβ)8 barrel around the [4Fe-4S]2+
cluster (orange), S-adenosylmethionine (red), DTB (green), and the
[2Fe-2S]2+ cluster (yellow) [8]. The C terminus is disordered and Selected Reading
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Khosla and coworkers report the synthesis of pep- t
tidic dihydroisoxazole derivatives, the in vitro evalua- o
tion of these novel compounds as inhibitors of re- o
combinant human tissue transglutaminase (TG2), and mheir oral bioavailability and efficacy for the synergis-
ic treatment of glioblastoma tumors [1].
n this issue, Chaitan Khosla and his coworkers report
he synthesis of novel peptidic dihydroisoxazole deriva-
ives, the results of their in vitro evaluation as inhibitors
f human tissue transglutaminase (TG2), and the dem-
nstration of their bioavailability and efficacy in an ani-
al model [1]. Their inspiring results derive from an im-
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411pressively broad multidisciplinary research effort, as
the title of the article suggests. To fully appreciate the
extensive impact of this outstanding work, the context
of three different aspects of the article merit particular
attention: (1) the peptidic structure of their inhibitors,
(2) the current lack of direct structural information that
would facilitate the structure-based design of TG2 in-
hibitors, and (3) the clear implication of TG2 in diverse
physiological disorders.
The novel inhibitors highlighted in Khosla’s article
feature a simple peptidic scaffold bearing a halo-dihy-
droisoxazole group. This particular pharmacophore
has proven effective for the inhibition of a number of
enzymes whose active sites resemble those of the cys-
teine proteases, including TG2 [2]. Likewise, the pep-
tidic framework of Khosla’s current series of dihydro-
isoxazole (DHI) inhibitors is also noteworthy. The
importance of a Cbz protecting group for conferring af-
finity to TG2 substrates was demonstrated 40 years
ago by Folk and Cole [3]. Around 20 years later, Krantz
also published results suggesting that in a series of var-
ied peptides bearing DHI groups, only Cbz-Phe- and
Cbz-Tyr-based scaffolds were reactive as inhibitors [2].
Khosla’s current work provides more detail, confirming
that aromatic amino acids bearing certain aromatic pro-
tecting groups are simple, synthetically accessible
scaffolds whose derivatives are among the few small
molecules having submillimolar affinity constants for
TG2. By way of comparison, previous work [4–6] featur-
ing the use of Cbz-X scaffolds have shown similar affin-
ity, where X is a glutamine analog bearing the inhibitory
functional group. More recent work featuring nonpep-
tidic heterocyclic compounds further supports the hy-
pothesis that an extended aromatic framework is im-
portant for TG2 affinity [7]. Moreover, certain peptides
based on native protein sequences have been shown
to have high affinity for TG2. These include PQPQLPY,
identified by Khosla from the wheat protein gliadin [8],
KVLDGQDP, deriving from the pro-elafin peptide [9],
and PKPQQFM, from the Substance P protein [10],
where the underlined glutamine residue indicates TG2
chemoselectivity.
Are there similarities between these molecules that
can be accounted for by a common binding model with
TG2? Certainly the hydrophobic nature of the residues
flanking the active site-reactive functional group is
immediately obvious in all of the most potent TG2 in-
hibitors reported to date. Cursory inspection of the pro-
line-rich sequences of the peptide substrates further
indicates that an extended hydrophobic rod-like con-
formation may be important for TG2 affinity. This spec-
ulative conformation and hydrophobic character would
certainly be complementary to the shallow groove on
the surface of TG2 that has been identified as the pep-
tide-bound glutamine binding site [11, 12]. Unfortu-
nately, a more comprehensive structural analysis allow-
ing the rational design of high-affinity inhibitors is
currently hindered by the lack of a single crystal struc-
ture of active TG2 from any source. For example, the
structure of human TG2 has been published, but in its
inactive form, with a bound GDP ligand [13]. The struc-
ture of the analogous red sea bream TG2 has also been
solved, but in the absence of the Ca2+ ligand necessary
for its activity [11]. Modeling studies based on the latterstructure have shown that in its inactive form, the active
site of TG2 is inaccessible to substrate and must be
manipulated in silico to permit subsequent docking ex-
periments [12]. Clearly, if we are to glean a more so-
phisticated level of understanding of the nature of the
interactions between TG2 and effective inhibitors such
as Khosla’s, information deriving from crystallographic
studies of human TG2 with bound active site inhibitors
(or inactive TG2 mutants with bound substrate) is abso-
lutely vital.
The urgency of this requirement is underlined by the
critical role that TG2 plays in serious physiological dis-
orders. Granted, the implication of TG2, a widespread
enzyme, in a given physiological disorder based solely
on its in vitro activity toward a particular native protein
as a substrate is preliminary at best, given the enzyme’s
broad specificity with respect to the sequence of amino
acids flanking the peptide bound glutamine and lysine
residues that serve as acyl donor and acceptor sub-
strates. However, many researchers, like Khosla, have
recently undertaken the collaborative and multidiscipli-
nary studies necessary to move beyond preliminary im-
plication, to convincingly confirm the physiological
benefit of TG2 inhibition in the context of specific disor-
ders. Among others, one of these disorders is Hunting-
ton’s disease, a neurodegenerative disease where TG2
appears to catalyze the transamidation of poly-Gln se-
quences of certain neuropeptides, leading to their ag-
gregation [14, 15]. Another example is Celiac Sprue, an
intestinal inflammatory disorder shown by Khosla and
coworkers [8, 16] to involve the TG2-mediated deami-
dation of a glutamine residue to a glutamate residue,
within a small peptide resulting from the partial proteo-
lytic digestion of a gluten protein. The resulting peptide,
now containing a glutamate residue, initiates in turn a T
cell-mediated inflammatory response. Finally, previous
work has implicated extracellular TG2 in mediating cel-
lular adhesion and migratory processes, particularly re-
levant in the metastasis of tumor cells [17]. Herein,
Khosla and his coworkers additionally demonstrate
that glioblastoma cells can be rendered chemosensi-
tive upon inhibition of TG2. Furthermore, the prepara-
tion of a fluorescent derivative of their irreversible inhib-
itor allowed them to localize this inhibitory activity on a
cellular level.
In summary, Khosla and his coworkers have prepared
a series of small-molecule, irreversible inhibitors of
TG2, based on the structure of previous peptidic com-
pounds having known in vitro inhibitory activity and
without the benefit of an appropriate structural model
of TG2. Evaluation of the in vitro activity of these novel
inhibitors was followed-up by an evaluation of specific
in vivo activity and the miscroscopic localization of a
fluorescent derivative. In this way, the authors provide
direct information regarding the physiological role of
TG2 in Celiac Sprue, demonstrate the therapeutic valid-
ity of the use of TG2 inhibitors for the treatment of glio-
blastomas, and provide a diagnostic tool for evaluation
of other TG2-dependent disease models. This thorough
collaborative effort demonstrates visibly how multidis-
ciplinary work at the interface of chemistry and biology
can contribute so distinctively and significantly to
both fields.
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